As Novartis’ Glivec Hearing Approaches, Indian IP Panel Adds Court-Ordered Technical Member
This article was originally published in PharmAsia News
NEW DELHI - Swiss pharma giant Novartis is "pleased" with the appointment of a new technical member to an Indian panel hearing a high-profile challenge by Novartis regarding the rejection of patent protection for its blockbuster leukemia drug Glivec
You may also be interested in...
MUMBAI - Multinational pharmaceutical companies eyeing the growing Indian market may find themselves confronting a challenging patent environment during the next few years as public interest groups look to further intensify patent oppositions
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).